These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27641943)

  • 21. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
    Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
    Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells.
    Nemade H; Chaudhari U; Acharya A; Hescheler J; Hengstler JG; Papadopoulos S; Sachinidis A
    Arch Toxicol; 2018 Apr; 92(4):1507-1524. PubMed ID: 29397400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An in silico-in vitro pipeline for drug cardiotoxicity screening identifies ionic pro-arrhythmia mechanisms.
    Clark AP; Wei S; Kalola D; Krogh-Madsen T; Christini DJ
    Br J Pharmacol; 2022 Oct; 179(20):4829-4843. PubMed ID: 35781252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into cardiotoxicity caused by chemotherapeutic agents.
    Grieve DJ; Davidson SM
    Br J Pharmacol; 2017 Nov; 174(21):3675-3676. PubMed ID: 29046013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes: a Critical Step for Drug Development and Cell Therapy.
    Tan SH; Ye L
    J Cardiovasc Transl Res; 2018 Oct; 11(5):375-392. PubMed ID: 29557052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
    Takasuna K; Kazusa K; Hayakawa T
    Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
    Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes (hPSC-CMs) Using Multi-electrode Arrays (MEAs).
    Sala L; Ward-van Oostwaard D; Tertoolen LGJ; Mummery CL; Bellin M
    J Vis Exp; 2017 May; (123):. PubMed ID: 28570546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human pluripotent stem cell-derived cardiomyocyte based models for cardiotoxicity and drug discovery.
    Zhao Y; Korolj A; Feric N; Radisic M
    Expert Opin Drug Saf; 2016 Nov; 15(11):1455-1458. PubMed ID: 27560951
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
    Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
    Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
    Denning C; Borgdorff V; Crutchley J; Firth KS; George V; Kalra S; Kondrashov A; Hoang MD; Mosqueira D; Patel A; Prodanov L; Rajamohan D; Skarnes WC; Smith JG; Young LE
    Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1728-48. PubMed ID: 26524115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening.
    Khan JM; Lyon AR; Harding SE
    Br J Pharmacol; 2013 May; 169(2):304-17. PubMed ID: 22845396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-mediated maturation of human pluripotent stem cell-derived cardiomyocytes: Towards a better model for cardiotoxicity?
    White MC; Pang L; Yang X
    Food Chem Toxicol; 2016 Dec; 98(Pt A):17-24. PubMed ID: 27265266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promotion of maturation of human pluripotent stem cell-derived cardiomyocytes via treatment with the peroxisome proliferator-activated receptor alpha agonist Fenofibrate.
    Lee SG; Rhee J; Seok J; Kim J; Kim MW; Song GE; Park S; Jeong KS; Lee S; Lee YH; Jeong Y; Kim CY; Chung HM
    Stem Cells Transl Med; 2024 Aug; 13(8):750-762. PubMed ID: 38946019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Hortigon-Vinagre MP; Zamora V; Burton FL; Smith GL
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):280-290. PubMed ID: 33109927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
    Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
    Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
    Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
    Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.